A multifactorial approach to complaints during the climacteric

Veeninga, Arend T.; Kraaimaat, Floris W.

doi:10.1080/02646839508403237

Cited by 7 publications

(8 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To determine perimenopausal women’s self-stereotype, we used a survey (S6 File: Appendix F Measurement of menopausal self-stereotype) developed for the purpose of this study [41]. Next, to identify participants’ attitudes toward the menopausal woman, we adopted the following criteria based on literature review [6,10,14,15,19,22,23,42–44] and the findings of a previous pilot study [41]:…”

Section: Methodsmentioning

confidence: 99%

“…The second model, by Veeninga and Kraaimaat, is multifactorial and refers to the development of bodily experiences and mood states during the climacteric, suggesting that the experience of menopause depends on the very process of perceiving and assessing menopausal symptoms [15]. The process can be modified as a consequence of focusing on the symptoms from the body in the context of the woman’s earlier experiences and social and individual expectations, which affect the way how perimenopausal women experience their bodies [14,26].…”

Section: Introductionmentioning

confidence: 99%

“…Based on literature review, we assumed that perimenopausal women’s SQH has three dimensions and depends on four variables: personality traits, self-esteem, body self, and self-stereotype [2,4–6,9,10–12,14–15,20,22–26].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Searching for predictors of sense of quality of health: A study using neural networks on a sample of perimenopausal women

Włodarczyk

Dolińska-Zygmunt

2019

PLoS ONE

View full text Add to dashboard Cite

BackgroundWe assumed that perimenopausal women’s sense of quality of health (SQH) is a subjective evaluation of their psycho-physical health, and comprises three dimensions: sense of quality of life, menopausal symptoms, and the level of positive and negative affect.PurposeThe aim of the study was to: 1) test a model about SQH, and 2) explore the role of personality traits, self-esteem, body self, and self-stereotype as predictors of SQH.MethodsThe sample included 201 women aged between 45 and 55 (50.11±3.07). Participants filled out the Rosenberg Self-Esteem Scale, the Personality Inventory based on the Big Five Factor Model, the Body Self Questionnaire, and a survey querying perimenopausal women’s self-stereotype. To determine the individual SQH dimensions we used the Sense of Quality of Life Questionnaire, the Menopause Symptom List, and the Positive and Negative Affect Schedule. To verify the assumptions of the SQH model and look for SQH predictors we conducted a neural networks analysis with structure optimization via genetic algorithms (a multivariate analysis).ResultsThe SQH model was verified in the course of several neural networks analyses with structure optimization via genetic algorithms (R = 0.849, R2 = 0.723, F = 133,232, p < 0.01). Moreover, we confirmed that SQH comprised three dimensions: quality of life, menopausal symptoms, and affect. SQH and menopausal symptoms were correlated. Similarly, positive and negative affect modified the women’s global sense of quality of life. SQH predictors included: personality traits, self-esteem, the body-self, and menopausal woman’s self-stereotype.ConclusionIn practical terms, our findings may help raise awareness among women and medical practitioners, calling for a holistic approach to the health of menopausal women. Our findings may also facilitate the creation of both prevention and therapeutic programs for women transitioning through menopause, for example, cognitive-behavioral therapy.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Searching for predictors of sense of quality of health: A study using neural networks on a sample of perimenopausal women

Włodarczyk

Dolińska-Zygmunt

2019

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Some studies have reported benefits of HT on psychological symptoms, while others found that this therapy has no greater effect than placebo (5,6).…”

Section: Introductionmentioning

confidence: 98%

Semptomatik Postmenopozal Kadınlarda İki Farklı Hormon Terapisinin Ruhsal Durum Üzerine Etkilerinin Karşılaştırılması

...

2012

npa

View full text Add to dashboard Cite

Objective: To investigate the effects of two different hormone therapies on menopausal symptoms, depression and anxiety scores in women with symptomatic natural menopause.Methods: 183 patients completed the study. Group I patients were treated with transdermal estradiol and oral norethisterone acetate. Group II patients were treated with oral continuous combination of noretbisterone and estradiol bemibydrate. Group III (control group) patients were administered placebo. Tbe treatment protocols were used for three months in all groups. Menopausal, depression and anxiety symptoms of the patients were assessed using the Kupperman scale, Hamilton Depression Rating Scale (HDRS) and the Beck Anxiety Inventory (BAI) before and at tbe end of treatment Results: Significant improvement was observed in menopausal symptoms, depression and anxiety scores in all groups at the end of three montbs of therapy (p<0.001). When the three groups were compared for all parameters before and after treatment, groups I and II showed better results tban group III (p<0.001).Conclusion: Transdermal or oral estradiol in combination witb norethisterone improves scores of menopausal, depression and anxiety symptoms in women with symptomatic natural menopause. (Archives of Neuropsychiatry 2012:49:39-43) Amaç: Semptomatik dogal menopoz dönemindeki kadmlarda iki farkli hormón tedavisinin etkileri ile control grubunda menopoz, depresyon ve anksiyete belirtilerinin kar §ila §tinlmasi amaçlanmi §tir. Yöntem 1er: Yüz seksen ijç hasta çaliçmayi tamamladi. I. Gruptaki hastalar oral noretisteron asetat ve transdermal östradiol ile tedavi edildiler. II. Gruptaki hastalar oral noretisteron ve östradiol hemihidrat kombinasyonu ile tedavi edildiler. III. Gruptaki hastalar (control grubu) placebo uygulandi. Tedavi protokolij tüm gruplarda 3 ay uygulandi. Hastalarin menopozal, depresyon ve anksiyete belirtileri tedavinin baçinda ve tedaviriin sonunda Kupperman Öicegi, Hamilton Depresyon Öicegi ve Beck Anksiyete Öicegi ile degerlendirildi. Bulgular: Üc aylik tedavi süresinin sonunda tijm gruplarda menopoz, depresyon ve anksiyete belirtilerinin anlamli ölcüde azaldigi (p<0,001) gözlendi. Tedavinin baçlangici ve sonunda zamana göre üc grubunun tüm degerlerini kar §ila §tirdigimizda I ve II grubun degerlerinin III. gruba gore daha lyi oldugu bulundu (p< 0,001).Sonuç: Trandermal veya oral östradiol ile noretisteron kombinasyonu, semptomatik dogal menopozlu kadinlarda menopoz ve depresyon ve anksiyete degerlerini iyileçtirmektedir. (NöropsikiyatriAr^ivi2012:49:39-43) Anahtar kelimeler: Menopoz, östradiol, noretisteron asetat, psikiyatri, depresyon

show abstract

“…Some studies report benefits of Hormone Therapy (HT) on psychological symptoms, others find no greater effect than placebo (3,4).…”

Section: Introductionmentioning

confidence: 99%

Effects of tibolone on depressive and anxiety symptoms in symptomatic postmenopausal women / Semptomatik postmenopozal kadınlarda tibolonun aksiyete ve depresif belirtiler üzerindeki etkileri

Karsidag¹,

Karşıdağ²,

Büyükbayrak³

et al. 2012

Dusunen Adam

View full text Add to dashboard Cite

Effects of tibolone on depressive and anxiety symptoms in symptomatic postmenopausal women Aims: We investigated the effect of tibolone therapy on menopausal symptoms, depression and anxiety scores in women with symptomatic natural menopause compared to control group using Kupperman's Index, Hamilton Depression Rating Scale and Beck Anxiety Inventory. Methods: One hundred thirty patients with menopausal symptoms enrolled into the study, and 121 patients completed. Group I patients were treated with tibolone 2.5 mg/day. Group II patients received placebo (calcium forte tablet 1000 mg/day). The menopausal, depressive and anxiety symptoms were assessed using Kupperman's Index, Hamilton Depression Rating Scale and Beck Anxiety Inventory before and at the end of the treatment For statistical analysis, paired t, multivariate analyses tests were used. Results: At the end of 3 months of therapy, we observed significant improvement in menopausal symptoms, depression and anxiety scores in both groups. When we compared two groups' Kupperman and Beck Anxiety Inventory (BDI) scores according to time before and after the treatment. Group I scored better than Group II. The superiority of tibolone comparing placebo on depressive symptoms could not be shown in this study. Conclusion: Tibolone's effects in calming vasomotor symptoms and improving anxiety symptoms suggest. it as an alternative when the possible side effects of estrogen and progesterone combination or estrogen alone are taken into account.

show abstract

A multifactorial approach to complaints during the climacteric

Cited by 7 publications

References 25 publications

Searching for predictors of sense of quality of health: A study using neural networks on a sample of perimenopausal women

Searching for predictors of sense of quality of health: A study using neural networks on a sample of perimenopausal women

Semptomatik Postmenopozal Kadınlarda İki Farklı Hormon Terapisinin Ruhsal Durum Üzerine Etkilerinin Karşılaştırılması

Effects of tibolone on depressive and anxiety symptoms in symptomatic postmenopausal women / Semptomatik postmenopozal kadınlarda tibolonun aksiyete ve depresif belirtiler üzerindeki etkileri

Contact Info

Product

Resources

About